Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase

Published:2018 Issue:7 Volume:8 Page:1808-1823
ISSN:1838-7640
Container-title:Theranostics
language:en
Short-container-title:Theranostics

Author:

Dong Jiang-Kai,Lei Hui-Min,Liang Qian,Tang Ya-Bin,Zhou Ye,Wang Yang,Zhang Shengzhe,Li Wen-Bin,Tong Yunguang,Zhuang Guanglei,Zhang Liang,Chen Hong-Zhuan,Zhu Liang,Shen Ying

Publisher

Ivyspring International Publisher

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Medicine (miscellaneous)

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation;Current Issues in Molecular Biology;2024-07-16

2. GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma;Oncogene;2024-07-05

3. Selenomethionine suppresses head and neck squamous cell carcinoma progression through TopBP1/ATR and TCAB1 signaling;HISTOL HISTOPATHOL;2024

4. PHGDH: a novel therapeutic target in cancer;Experimental & Molecular Medicine;2024-07-01

5. Cellular Responses Induced by NCT-503 Treatment on Triple-Negative Breast Cancer Cell Lines: A Proteomics Approach;Biomedicines;2024-05-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP